The hormonal deficit of post menopause is not only linked to the classic hot flashes, but also to a higher risk of chronic diseases.
Menopausal hormone therapy (MHT) adequately treats climacteric symptoms and can prevent some chronic diseases such as osteoporosis. The Women's Health Initiative (WHI) study, which indicated risks of MHT in elderly postmenopausal women, caused a massive withdrawal of this therapy in 1991.
But, in recent years the results of the WHI have been challenged because of methodological problems by several studies indicating that, if MHT is initiated early and the non-oral route is preferred, the risks could be minimized and it could improve not only the quality of life but also reduce the risk of chronic diseases.
However, the US Preventive Services Task Force (USPSTF) recommends against the use of MHT for the prevention of chronic diseases, a position that has been challenged by publications of the North American Menopause Society and the International Menopause Society.
We believe bioidentical hormone replacement therapy (b HRT) can be done effectively and safely when all female hormones are prescribed in balance and when levels are not driven to supra-physiologic (very high) such as is seen with pellet therapy or injections.
The term "bioidentical" means the hormones in the product are chemically identical to those your body produces.
Familiar examples of hormones that women are prescribed that are not bio identical include ALL birth control pills and Premarin.